# 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY

A. 510(k) Number: k123127   
B. Purpose for Submission: New device   
C. Measurand: Multi-analyte control materials   
D. Type of Test: Quantitative, Immunoassay   
E. Applicant: Maine Standards Company LLC

F. Proprietary and Established Names: VALIDATE $^ \mathrm { \textregistered }$ PSA Calibration Verification/ Linearity Test Kit

# G. Regulatory Information:

1. Regulation section: 21 CFR $\ S$ 862.1660 Quality Control Material (assayed and unassayed)

2. Classification: Class I, reserved

3. Product code: JJY – Multi-analyte controls, all kinds (assayed)

4. Panel: Chemistry (75)

# H. Intended Use:

1. Intended use(s):

VALIDATE $^ \mathrm { \textregistered }$ PSA Calibration/ Verification/ Linearity Test Kit solutions are intended for in vitro diagnostic use in the quantitative determination of linearity, calibration verification and verification of reportable range for the following analytes: Total prostrate-specific antigen (PSA) and free prostrate-specific antigen (fPSA) on automated systems.

2. Indication(s) for use: Same as Intended use.

For In Vitro Diagnostic Use. For prescription only.

The kit is not intended for use as routine quality control material or as calibration materials.

4. Special instrument requirements: Automated analyzer systems

# I. Device Description:

Each test kit consists of one bottle each of Levels 1 through 6 plus a Base matrix. Each bottle contains $2 . 5 ~ \mathrm { m L }$ each level, ready to use. There exists a linear relationship among Levels 1 through 6.

Material of human origin used in the manufacture of this test kit has been tested using FDA or CE approved methods and found to be non-reactive for HBV, HCV and HIV.

# J. Substantial Equivalence Information:

1. Predicate device name(s): VALIDATE $^ \mathrm { \textregistered }$ Chem 6 Calibration Verification Test Set

2. Predicate 510(k) number(s): k013119 (for Uric Acid)

3. Comparison with predicate:

<table><tr><td rowspan=1 colspan=3>Similarities</td></tr><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>Device</td><td rowspan=1 colspan=1>Predicate</td></tr><tr><td rowspan=1 colspan=1>Test kit</td><td rowspan=1 colspan=1>Calibration VerificationTest Kit</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Stability</td><td rowspan=1 colspan=1>Until expiration date</td><td rowspan=1 colspan=1>Same</td></tr></table>

<table><tr><td rowspan=1 colspan=3>Differences</td></tr><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>Device</td><td rowspan=1 colspan=1>Predicate</td></tr><tr><td rowspan=1 colspan=1>Intended Use</td><td rowspan=1 colspan=1>VALIDATE PSACalibration Verification/Linearity Test Kit forautomated systems</td><td rowspan=1 colspan=1>VALIDATE Chem 6Calibration VerificationTest Set for Uric Acid inautomated, semi-automatedand manual instrumentsystems</td></tr><tr><td rowspan=1 colspan=1>Analytes</td><td rowspan=1 colspan=1>Total PSA and Free PSA</td><td rowspan=1 colspan=1>Uric Acid</td></tr><tr><td rowspan=1 colspan=1>Matrix</td><td rowspan=1 colspan=1>Human serum based</td><td rowspan=1 colspan=1>Aqueous solution</td></tr><tr><td rowspan=1 colspan=1>Number of levels</td><td rowspan=1 colspan=1>6 Levels</td><td rowspan=1 colspan=1>5 Levels plus a level zero</td></tr><tr><td rowspan=1 colspan=1>Packaging</td><td rowspan=1 colspan=1>2.5 mL each level</td><td rowspan=1 colspan=1>5.0 mL each level</td></tr><tr><td rowspan=1 colspan=1>Storage</td><td rowspan=1 colspan=1>-10 to -25°C</td><td rowspan=1 colspan=1>2-8°C</td></tr></table>

# K. Standard/Guidance Document Referenced (if applicable):

Not applicable

L. Test Principle: Not applicable

# M. Performance Characteristics (if/when applicable):

1. Analytical performance:

a. Precision/Reproducibility: Not applicable

b. Linearity/assay reportable range:

A total of six linear dilution levels of Total PSA and Free PSA were tested in triplicate ranging between $0 . 0 1 \mathrm { ~ - ~ } 1 4 8 . 2 \mathrm { n g / m L }$ for Total PSA and $0 . 0 0 8 \mathrm { ~ - ~ } 6 2 . 6 ~ \mathrm { n g / m L }$ for Free PSA on representative automated analyzers. Linear regression analysis results are tabulated below. Criteria of acceptability with total allowable error of 0.3 $\mathrm { { n g / m L } }$ or $32 \%$ whichever is greater. Linearity claims for these products are: Total PSA: $0 . 0 0 8 \mathrm { - } 1 5 0 ~ \mathrm { n g / m L }$ and Free PSA: $0 . 0 0 5 { - } 5 0 \mathrm { n g / m L }$ .

Linearity was determined using CLSI EP6-A. Results for Total and Free PSA are summarized in the following tables:

<table><tr><td rowspan=1 colspan=2>Validate® Total PSA</td></tr><tr><td rowspan=1 colspan=1>Automated analyzer</td><td rowspan=1 colspan=1>Mean vs Target Regression</td></tr><tr><td rowspan=1 colspan=1>Beckman-Coulter® Access IIImmunochemistry Analyzer</td><td rowspan=1 colspan=1>y = 0.974x + 0.951</td></tr><tr><td rowspan=1 colspan=1>Roche® Cobas 6000 ChemistryAnalyzer</td><td rowspan=1 colspan=1>y = 1.024x - 0.042</td></tr><tr><td rowspan=1 colspan=1>Siemens® CentaurImmunochemistry Analyzer</td><td rowspan=1 colspan=1>y = 1.009x - 0.127</td></tr></table>

<table><tr><td rowspan=1 colspan=2>Validate® Free PSA</td></tr><tr><td rowspan=1 colspan=1>Automated analyzer</td><td rowspan=1 colspan=1>Mean vs Target Regression</td></tr><tr><td rowspan=1 colspan=1>Beckman-Coulter® Access IIImmunochemistry Analyzer</td><td rowspan=1 colspan=1>y = 1.042x - 0.382</td></tr><tr><td rowspan=1 colspan=1>Roche® Cobas 6000 ChemistryAnalyzer</td><td rowspan=1 colspan=1>y = 0.920x + 0.484</td></tr></table>

c. Traceability, Stability, Expected values (controls, calibrators, or methods):

Traceability: Values of this product are linked to the WHO PSA standard based on the respective instrument calibration traceability.

Stability: The sponsor provided protocol, acceptance criteria, and line data with summary.

Real time stability study on the 6 level vials is on-going. Data from 3 lots support 3 months shelf life and 2 lots for 4 months for opened vial.

Open vial freeze-thaw study on 6 levels of Total PSA and Free PSA were performed for 6 freeze-thaw cycles. Data support maximum of 4 freeze/ thaw cycle.

d. Detection limit: Not applicable   
e. Analytical specificity: Not applicable   
f. Assay cut-off: Not applicable

2. Comparison studies:

a. Method comparison with predicate device: Not applicable.

b. Matrix comparison: Not applicable

3. Clinical studies:

a. Clinical Sensitivity: Not applicable

b. Clinical specificity: Not applicable   
c. Other clinical supportive data (when a. and b. are not applicable): Not applicable

4. Clinical cut-off: Not applicable

5. Expected values/Reference range: Not applicable

# N. Proposed Labeling:

The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.

# O. Conclusion:

The submitted information in this premarket notification is complete and supports a substantial equivalence decision.